Sutro Biopharma

NMQ:STRO · US8693672011

BiotechnologySmall

360

Value43

Profit price36

Cash yield1

Owner Earnings Yield1

Dividend Yield1

Sales & asset price68

Price/Sales57

Price/Book78

Quality46

Returns on capital100

Profit margins17

EBIT Margin19

Gross Profitability14

Cash backing44

Accruals55

Owner Earnings Margin33

Growth50

Sales growth26

Profit growth47

Reinvestment67

Price momentum86

Safety32

Debt load70

Debt serviceability4

Refinancing7

Debt Payback1

Liquidity91

Sentiment39

Analyst ratings27

Expectations trend29

Opinion Changes26

Price Target Upside32

Market mood91

Value Creation0/20not creating value

Creates more value than its capital costs
Owner earnings growing
Owner earnings per share growing
Reinvests at strong returns
Solid earnings base

What this means

Sutro Biopharma doesn't consistently earn more than its cost of capital, so it isn't yet creating shareholder value.

Based on 3/5 components.

Profile

CountryUSA

IndustryBiotechnology

SizeSmall

TypePublic Company

ExchangeNASDAQGM

Founded2003

Employees214

Websitesutrobio.com

ISINUS8693672011

Last UpdateApr 2, 2026

Indices

NASDAQ (USA)

Themes

ImmunologyVaccinesInfectious DiseasesOncologyBiotechnologyInformation TechnologyMedical

Description

Sutro Biopharma, Inc., an oncology company, develops site-specific and novel-format antibody drug conjugates, or ADCs, enabled by its proprietary integrated cell-free protein synthesis platform, XpressCF, and its site-specific conjugation platform, X…

Analysis

Middle-of-the-road

Sutro Biopharma, Inc. sits in the middle of our grid: average quality, average price, no obvious signal in either direction.

Valuation data is not available for this company.

Growth is moderate; the safety picture is stretched. The company scores 0/20 on our value-creation score: not creating value. Analyst sentiment is cautious.

Flags to be aware of: Some accounting patterns deserve a closer look. As always: this describes the company's numbers; it is not a recommendation.

360° rank · history

1007550250

2026

All-time high

Mar 2026

All-time low

Jun 2026

Average rank

across all years

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023

Price/Sales

—

Price/Earnings

—

Price/Book

—

Dividend Yield

—

Value (overall)

—

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Sutro Biopharma with its peers

Crescent Biopharma

NAQ:CBIO

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

ArriVent BioPharma

NMQ:AVBP

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Zymeworks

NSQ:ZYME

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Tharimmune

NAQ:THAR

—

CountryUSA

IndustryBiotechnology

SizeX-Small

Full Stock Analysis →

Oruka Therapeutics

NMQ:ORKA

—

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Prelude Therapeutics

NSQ:PRLD

CountryUSA

IndustryBiotechnology

SizeSmall

Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View

1 · Watch OutGood· 100

Value

1 · ExpensiveGood Value· 100

Quality

1 · Weak FundamentalsHigh Quality· 100

Growth

1 · Tough TimesHigh Growth· 100

Safety

1 · High LeverageWell-Financed· 100

Sentiment

1 · SkepticismPositive· 100

Learn More →